Alimta (Pemetrexed) Mesothelioma Treatment

Lilly Given OK To Make Alimta Available on Expanded Access Basis

INDIANAPOLIS--(BW HealthWire)--July 9, 2002--Eli Lilly and Company and the U.S. Food and Drug Administration have reached agreement to make Alimta ® (pemetrexed) available on an expanded access, or compassionate use, basis to medically eligible patients with malignant pleural mesothelioma, a devastating cancer usually associated with exposure to asbestos.

"What this essentially means is that qualified patients who have been diagnosed with malignant pleural mesothelioma and have not yet received treatment may be eligible to receive Alimta before, rather than after, the FDA review process," said Alan K. Hatfield, M.D., medical director, oncology, for Lilly's U.S. affiliate.

Expanded access programs are designed to make investigational agents available at the earliest opportunity for the treatment of patients with diseases for which no comparable or satisfactory alternative drug or other therapy is available. Under such programs, patients are given access to an agent that is not yet commercially available, although the sponsor is actively pursuing marketing approval.

Lilly is pursuing approval of Alimta in combination with cisplatin for the treatment of malignant pleural mesothelioma (MPM). In this disease, tumors grow in the linings of the lung, or pleura, and slowly suffocate the patient. By the time symptoms appear, the disease has usually progressed and patients live, on average, six to nine months following diagnosis. In addition to being characterized by a high mortality rate, MPM exacts an enormous physical toll -- severe, dense throbbing chest pain and chronic shortness of breath are hallmarks of this disease.

Under the expanded access program, Alimta will be available free of charge to patients with MPM who meet medical eligibility criteria.

"This is simply the right thing to do," said Paolo Paoletti, M.D., leader of the Alimta product team at Lilly. "The expanded access program provides hope for patients who are battling a devastating disease. It's clear to anyone who studies mesothelioma, or suffers from it, that patients and their families are in desperate need of treatment options."

In July 2002, The U.S. Food and Drug Administration and Eli Lilly Company announced that Alimta (pemetrexed) would be made available to patients with malignant pleural mesothelioma. The drug, a chemotherapy treatment is not fully FDA approved but will be made available to "qualified patients who have been diagnosed with malignant pleural mesothelioma and have not yet received treatment." The FDA allows Alimta to be used under a so-called "Expanded access program," that allows new treatments available to patients with diseases like mesothelioma, for which there is no other treatment or satisfactory alternative therapy. Under this program, patients with mesothelioma will be given access to Alimta while the FDA review process is going forward and the treatment is pending review.

Under the current expanded access program, Alimta may be available free to patients who qualify. Additionally, patients with mesothelioma may be entitled to large settlements against employers or asbestos makers.

 

 

If you would like more information about Mesothelioma or the availability of treatment options please contact us here.